重组细菌疫苗载体的最新进展。

Recent advances with recombinant bacterial vaccine vectors.

作者信息

Shata M T, Stevceva L, Agwale S, Lewis G K, Hone D M

机构信息

Division of Vaccine Research, Institute of Human Virology, 725 Lombard Street, Baltimore, MD 21201, USA.

出版信息

Mol Med Today. 2000 Feb;6(2):66-71. doi: 10.1016/s1357-4310(99)01633-0.

DOI:10.1016/s1357-4310(99)01633-0

PMID:10652479

Abstract

Bacille Calmette-Guerin (BCG), Listeria monocytogenes, Salmonellae and Shigellae have shown promise as vaccine vectors in experimental animal models. Although disappointing results in humans and non-human primates stalled the development of this vaccination strategy, interest in this approach was reinvigorated recently by the development of bacterial DNA-vaccine-vectors. The purpose of this review is to highlight the strengths and weaknesses of bacterial vaccine vectors, and to discuss the future prospects of these vaccine delivery systems.

摘要

卡介苗（BCG）、单核细胞增生李斯特菌、沙门氏菌和志贺氏菌在实验动物模型中已显示出作为疫苗载体的潜力。尽管在人类和非人类灵长类动物中取得的令人失望的结果使这种疫苗接种策略的发展陷入停滞，但最近细菌DNA疫苗载体的开发重新激发了人们对这种方法的兴趣。这篇综述的目的是突出细菌疫苗载体的优缺点，并讨论这些疫苗递送系统的未来前景。